Myoclonus
11
4
4
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
1 terminated out of 11 trials
80.0%
-6.5% vs benchmark
9%
1 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (11)
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
A Retrospective Survey-based Multicenter Study to Delineate the Molecular and Phenotypic Spectrum of Epilepsy-dyskinesia Syndromes
Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
Median Effective Dose of Remifentanil for the Prevention of Myoclonus Induced by Etomidate Injection
Electrophysiological Characteristics and Anatomical Differentiation of Epileptic and Non-epileptic Myoclonus.
Effects and Mechanism of Pretreatment With Dexmedetomidine to Etomidate Induce Myoclonus
Pilot Efficacy Study of T2000 in Myoclonus Dystonia
Effectiveness of Rituximab in Pediatric OMS Patients.
Genotype/Phenotype Correlation of Movement Disorders and Other Neurological Diseases
Treatment of Cortical Myoclonus With Repetitive Transcranial Magnetic Stimulation